South Rampart Pharma, a US-based clinical-stage life science company that said it is advancing innovative medications for the treatment of pain and fever, announced on Tuesday that it has named Josh Blacher as its new chief financial officer.
In the new role, Blacher will be responsible for the firm's finance and accounting department, and for introducing a robust corporate development effort.
Blacher has more than twenty years of leadership experience in senior positions in the healthcare and capital markets sectors. He helped build and handle Teva Innovative Ventures. He has held the position of CFO/CBO at three publicly traded biotechnology companies, the most recent of which was Inmed Pharmaceuticals. He has served in senior positions in portfolio management at Deutsche Asset Management and equity research at Morgan Stanley and in mergers & acquisitions at Lehman Brothers.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer